Boehringer
Jul 23, 2020
Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack
Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas. The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will a...
Read More...
Sep 23, 2019
Boehringer Ingelheim ties up with Inflammasome Therapeutics
Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
